ASP Isotopes (NASDAQ:ASPI) Stock Price Up 9.5% – Should You Buy?

ASP Isotopes Inc. (NASDAQ:ASPI)’s share price shot up 9.5% during mid-day trading on Wednesday . The stock traded as high as $5.88 and last traded at $5.9350. 2,066,211 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 5,507,850 shares. The stock had previously closed at $5.42.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Cantor Fitzgerald started coverage on ASP Isotopes in a report on Thursday, December 4th. They set an “overweight” rating and a $13.00 price objective for the company. Canaccord Genuity Group reissued a “buy” rating and set a $11.00 price target on shares of ASP Isotopes in a research note on Monday, November 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $13.00.

ASP Isotopes Price Performance

The company has a debt-to-equity ratio of 1.04, a quick ratio of 6.10 and a current ratio of 6.14. The company has a market capitalization of $636.22 million, a price-to-earnings ratio of -4.42 and a beta of 3.47. The company has a 50-day moving average price of $6.29 and a 200-day moving average price of $7.93.

Insider Activity at ASP Isotopes

In other ASP Isotopes news, CFO Heather Kiessling sold 80,000 shares of the stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $5.80, for a total value of $464,000.00. Following the sale, the chief financial officer directly owned 732,500 shares in the company, valued at approximately $4,248,500. This trade represents a 9.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Robert Ainscow sold 8,438 shares of ASP Isotopes stock in a transaction on Monday, December 8th. The stock was sold at an average price of $6.20, for a total transaction of $52,315.60. Following the transaction, the chief executive officer directly owned 1,546,255 shares in the company, valued at approximately $9,586,781. This represents a 0.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 250,591 shares of company stock worth $1,448,695. 14.40% of the stock is currently owned by company insiders.

Institutional Trading of ASP Isotopes

Several hedge funds have recently added to or reduced their stakes in the business. Pacer Advisors Inc. bought a new position in ASP Isotopes during the fourth quarter worth about $2,163,000. Compound Planning Inc. acquired a new stake in shares of ASP Isotopes during the fourth quarter worth about $82,000. Mercer Global Advisors Inc. ADV lifted its holdings in shares of ASP Isotopes by 21.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 25,550 shares of the company’s stock valued at $137,000 after purchasing an additional 4,494 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of ASP Isotopes in the 4th quarter valued at approximately $720,000. Finally, VARCOV Co. bought a new stake in ASP Isotopes during the 4th quarter worth approximately $1,009,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.